As of May 23, 2025, ExpreS2ion Biotech Holding AB has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $23.60, this represents a potential upside of -117686655.4%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -794463.3% |
| Potential Upside (10-year) | -117686655.4% |
| Discount Rate (WACC) | 4.8% - 6.9% |
Revenue is projected to grow from $8 million in 12-2024 to $463076 million by 12-2034, representing a compound annual growth rate of approximately 199.4%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2024 | 8 | 11% |
| 12-2025 | 8 | 3% |
| 12-2026 | 9 | 14% |
| 12-2027 | 208 | 2162% |
| 12-2028 | 775 | 273% |
| 12-2029 | 2689 | 247% |
| 12-2030 | 8633 | 221% |
| 12-2031 | 25864 | 200% |
| 12-2032 | 72098 | 179% |
| 12-2033 | 188678 | 162% |
| 12-2034 | 463076 | 145% |
Net profit margin is expected to improve from -465% in 12-2024 to -458% by 12-2034, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2024 | (36) | -465% |
| 12-2025 | (41) | -509% |
| 12-2026 | (46) | -498% |
| 12-2027 | (1,013) | -487% |
| 12-2028 | (3,698) | -477% |
| 12-2029 | (12,567) | -467% |
| 12-2030 | (40,186) | -465% |
| 12-2031 | (119,923) | -464% |
| 12-2032 | (333,001) | -462% |
| 12-2033 | (868,112) | -460% |
| 12-2034 | (2,122,504) | -458% |
with a 5-year average of $1 million. Projected CapEx is expected to maintain at approximately 10% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2025 | 1 |
| 12-2026 | 1 |
| 12-2027 | 5 |
| 12-2028 | 21 |
| 12-2029 | 76 |
| 12-2030 | 252 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 48 |
| Days Inventory | 0 |
| Days Payables | 137 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2025 | (68) | (4) | 1 | 1 | (66) |
| 2026 | (76) | (4) | 1 | 1 | (74) |
| 2027 | (1,718) | (95) | 21 | (134) | (1,510) |
| 2028 | (6,315) | (347) | 79 | (322) | (5,726) |
| 2029 | (21,619) | (1,178) | 276 | (986) | (19,731) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -794463.3% |
| 10-Year DCF (Growth) | 0.00 | -117686655.4% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is ExpreS2ion Biotech Holding AB (EXPRS2.ST) a buy or a sell? ExpreS2ion Biotech Holding AB is definitely a sell. Based on our DCF analysis, ExpreS2ion Biotech Holding AB (EXPRS2.ST) appears to be overvalued with upside potential of -117686655.4%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $23.60.